ImmunityBio Inc (IBRX) concluded trading on 01/11/24 at a closing price of $3.97, with 3.41 million shares of worth about $13.53 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.04% during that period and on Thursday the price saw a loss of about -5.25%. Currently the company’s common shares owned by public are about 421.57M shares, out of which, 130.82M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 16 times over the past 12 months. They bought 209,661,029 shares in 15 of the transactions. In 1 selling transactions, insiders dumped 42,192 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the stock later moved at a day high price of 4.1800, or with a loss of -5.25%. Stock saw a price change of -17.81% in past 5 days and over the past one month there was a price change of 24.84%. Year-to-date (YTD), IBRX shares are showing a performance of -20.92% which decreased to -9.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.21 but also hit the highest price of $6.93 during that period. The average intraday trading volume for ImmunityBio Inc shares is 6.08 million. The stock is currently trading -11.44% below its 20-day simple moving average (SMA20), while that difference is down -0.54% for SMA50 and it goes to 46.95% higher than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 421.57M outstanding shares and institutions hold larger chunk of about 7.51% of that.
The stock has a current market capitalization of $2.65B and its 3Y-monthly beta is at 1.05. It has posted earnings per share of -$1.05 in the same period. It has Quick Ratio of 2.38. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 7.97% while standing at 9.60% over the month.
Analysts are in expectations that ImmunityBio Inc (IBRX) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.16 and it is -$0.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.18 which is -$0.18 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.28 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 10.58% while it is estimated to increase by 26.88% in next year. EPS is likely to shrink at an annualized rate of -1.70% for next 5-years, compared to annual growth of 2.79% made by the stock over the past 5-years.
Analysts at 1 brokerage firms have issued recommendations for the ImmunityBio Inc (IBRX)’s stock and average of those rates the stock at a “Hold” and assign it a score of 3.00. Out of those 1 Wall Street analysts, 0 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $10 and $4 to it.
